François-Xavier Houde is a Senior Health Economist at PDCI. He is responsible for leading the conception and development of strategic, evidence-based economic components for submission to Canadian health Technology Assessment bodies and public/private payers. Among other roles, he ensures that PDCI is that forefront of trends and policy matters affecting HTA, pricing, market access and pharmaceutical industry.
François-Xavier has over 5 five years of experience at INESSS, working as a health economics advisor. During that time, he practiced pharmacy for a few years. This experience allows him to have a quick and thorough understanding of the clinical context, the patient needs and the economical considerations that pertain to a wide range of health technologies. Strong from over 50 health economics evaluation of sponsor submissions and in-house projects, François-Xavier developed an expertise in value-based pricing, pharmacoeconomic model adaptation, budget impact model building, and data extraction from patient-level databases.
Prior to joining PDCI in 2022, François-Xavier was scientific advisor in health economics at the Institut National d’Excellence en Santé et Services Sociaux (INESSS) where he gained experience in clinical and statistical evaluating, pharmacoeconomic and budget impact modelling, facilitating and assessing sponsor submissions.